Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases
Model scores of the 29,894 trials active now.
Model score 24% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).
Finished trial that started in 2015 or later: the model never saw it during training.
How it ended
Terminated on 2021-03-01, after 2017-11-03 start.
Reason given by the sponsor: “enrollment”
The score above never used this outcome: finished trial that started in 2015 or later: the model never saw it during training.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-03-01. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: ironsubjects withcancertherapytumor
Phrases that lowered it: the trialuse ofdrugvisitlong -
Sponsor's past termination rate: 47.9% (raises risk) · Sponsor's track record
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Phase: 2 (raises risk) · Design
-
Drug's FAERS reports marked serious: 64.8% (lowers risk) · Drug's FDA history
-
Drug's FAERS reports with a death: 9.5% (lowers risk) · Drug's FDA history
-
Design: single group (raises risk) · Design
-
Disease area, cancer: No (lowers risk) · Disease area
-
Has a data monitoring committee: Yes (raises risk) · Design
-
Drug's FAERS reports before start: 173535 (lowers risk) · Drug's FDA history
-
Minimum age: 18 (raises risk) · Who can join
-
Sponsor type: academic or other (raises risk) · Sponsor's track record
-
Drug's FAERS reports in the prior 12 months: 27646 (lowers risk) · Drug's FDA history
-
Primary purpose: treatment (raises risk) · Design
-
Collaborators: 2 (lowers risk) · Design
-
Maximum age: not given (raises risk) · Who can join
-
Drugs with FDA adverse-event history: 6 (lowers risk) · Drug's FDA history
-
Number of arms: 1 (raises risk) · Design
-
Blinding: none (raises risk) · Design
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 2
- Number of arms
- 1 (typical: 2)
- Allocation
- not applicable (typical: randomized)
- Design
- single group (typical: parallel)
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- Yes (typical: 56% yes)
- Responsible party
- principal investigator (typical: sponsor)
- Collaborators
- 2 (typical: 0)
- Keywords listed
- 0 (typical: 1)
Who can join
- Minimum age
- 18
- Maximum age
- not given (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- academic or other
- Sponsor's past trials
- 71 (typical: 32)
- Sponsor's past termination rate
- 47.9% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 12 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 6 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 173535 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 27646 (typical: 412.5)
- Drug's FAERS reports marked serious
- 64.8% (typical: 85.6%)
- Drug's FAERS reports with a death
- 9.5% (typical: 15.9%)
Disease area and drugs
- Disease areas
- none of the 14 tracked areas
- Drugs matched to FDA substances
- ferrosoferric, ferumoxytol, ferumoxytol non stoichiometric magnetite, lambrolizumab, oxide, pembrolizumab
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma NCT03347617 · started 2017 · scored riskier than 88% of active trials terminated
- Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer NCT03072160 · started 2017 · scored riskier than 98% of active trials completed
- Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 · started 2016 · scored riskier than 94% of active trials completed
- Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618 · started 2017 · scored riskier than 90% of active trials completed
- Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence NCT04013672 · started 2020 · scored riskier than 80% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.